96 related articles for article (PubMed ID: 26902334)
1. Prostate cancer: Multilayered mutation analysis indicates divergent clonal evolution.
Thoma C
Nat Rev Urol; 2016 Apr; 13(4):179. PubMed ID: 26902334
[No Abstract] [Full Text] [Related]
2. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Beltran H; Prandi D; Mosquera JM; Benelli M; Puca L; Cyrta J; Marotz C; Giannopoulou E; Chakravarthi BV; Varambally S; Tomlins SA; Nanus DM; Tagawa ST; Van Allen EM; Elemento O; Sboner A; Garraway LA; Rubin MA; Demichelis F
Nat Med; 2016 Mar; 22(3):298-305. PubMed ID: 26855148
[TBL] [Abstract][Full Text] [Related]
3. Genomic Aberrations Drive Clonal Evolution of Neuroendocrine Tumors.
Kaushik AK; Sreekumar A
Trends Endocrinol Metab; 2016 May; 27(5):242-244. PubMed ID: 27037211
[TBL] [Abstract][Full Text] [Related]
4. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
Buonerba C; Di Lorenzo G; Sonpavde G
Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
[TBL] [Abstract][Full Text] [Related]
5. Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?
Taplin ME; Balk SP
JAMA Oncol; 2015 Aug; 1(5):577-9. PubMed ID: 26181796
[No Abstract] [Full Text] [Related]
6. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
7. Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer.
Antonarakis ES; Luo J
J Urol; 2016 Dec; 196(6):1606-1607. PubMed ID: 27620214
[No Abstract] [Full Text] [Related]
8. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
Aggarwal RR; Quigley DA; Huang J; Zhang L; Beer TM; Rettig MB; Reiter RE; Gleave ME; Thomas GV; Foye A; Playdle D; Lloyd P; Chi KN; Evans CP; Lara PN; Feng FY; Alumkal JJ; Small EJ
Mol Cancer Res; 2019 Jun; 17(6):1235-1240. PubMed ID: 30918106
[TBL] [Abstract][Full Text] [Related]
9. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
10. Expression of STAT3 in Prostate Cancer Metastases.
Don-Doncow N; Marginean F; Coleman I; Nelson PS; Ehrnström R; Krzyzanowska A; Morrissey C; Hellsten R; Bjartell A
Eur Urol; 2017 Mar; 71(3):313-316. PubMed ID: 27344294
[TBL] [Abstract][Full Text] [Related]
11. Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis.
Liu YN; Yin J; Barrett B; Sheppard-Tillman H; Li D; Casey OM; Fang L; Hynes PG; Ameri AH; Kelly K
Mol Cell Biol; 2015 Jun; 35(11):1940-51. PubMed ID: 25802280
[TBL] [Abstract][Full Text] [Related]
12. [Hormone Resistance and Neuroendocrine Differentiation Due to Accumulation of Genetic Lesions during Clonal Evolution of Prostate Cancer].
Mikhaylenko DS; Efremov GD; Sivkov AV; Zaletaev DV
Mol Biol (Mosk); 2016; 50(1):34-43. PubMed ID: 27028809
[TBL] [Abstract][Full Text] [Related]
13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
[TBL] [Abstract][Full Text] [Related]
15. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
16. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
[TBL] [Abstract][Full Text] [Related]
17. Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth.
Sung SY; Chang JL; Chen KC; Yeh SD; Liu YR; Su YH; Hsueh CY; Chung LW; Hsieh CL
PLoS One; 2016; 11(4):e0153350. PubMed ID: 27054343
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives.
Hu J; Wang G; Sun T
Tumour Biol; 2017 May; 39(5):1010428317692259. PubMed ID: 28475016
[TBL] [Abstract][Full Text] [Related]
19. The roles of microRNAs in the progression of castration-resistant prostate cancer.
Kojima S; Goto Y; Naya Y
J Hum Genet; 2017 Jan; 62(1):25-31. PubMed ID: 27278789
[TBL] [Abstract][Full Text] [Related]
20. Re: Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Taneja SS
J Urol; 2015 Sep; 194(3):704. PubMed ID: 26292859
[No Abstract] [Full Text] [Related]
[Next] [New Search]
